Home
Business News
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
Related Posts
DULLES, Va. – Jan. 21, 2022 – Two Northrop Grumman Corporation (NYSE: NOC) Geosynchronous Space Situational Awareness Program (GSSAP) satellites…
Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam…
Keep metering equipment and vents clear Dominion Energy Ohio reminds customers that heavy, wet snow can block or damage metering…
BETHESDA, Md. , Jan. 21, 2022 /PRNewswire/ — Marriott International, Inc. (Nasdaq: MAR) will report fourth quarter 2021 earnings…
DOWNERS GROVE, Ill. , Jan. 21, 2022 /PRNewswire/ — SWEP , part of Dover (NYSE: DOV), today announced the introduction of…
NORTH CHICAGO, Ill., Jan. 21, 2022 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has…
Duke Energy and its power outage response crews are ready for this weekend’s winter storm in the Carolinas – the…
ST. AUGUSTINE, Fla. – Jan. 21, 2022 – (PHOTO RELEASE) Northrop Grumman Corporation (NYSE: NOC) successfully delivered the 51st U.S.…
In a year that continued to present audiences with an unprecedented variety of streaming platforms and content, U.S. consumers took…
Upon close, acquisition to position new standalone company for next phase of growth Please leave this field emptyGet every new…